Log in
NASDAQ:RETA

Reata Pharmaceuticals Competitors

$163.63
+0.87 (+0.53 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$159.62
Now: $163.63
$170.52
50-Day Range
$102.03
MA: $131.33
$184.62
52-Week Range
$88.17
Now: $163.63
$257.96
Volume196,591 shs
Average Volume356,757 shs
Market Capitalization$5.54 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.64

Competitors

Reata Pharmaceuticals (NASDAQ:RETA) Vs. CTLT, HZNP, ELAN, ALNY, BMRN, and GRFS

Should you be buying RETA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Reata Pharmaceuticals, including Catalent (CTLT), Horizon Therapeutics Public (HZNP), Elanco Animal Health (ELAN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), and Grifols (GRFS).

Catalent (NYSE:CTLT) and Reata Pharmaceuticals (NASDAQ:RETA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Earnings & Valuation

This table compares Catalent and Reata Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalent$3.09 billion5.31$173 million$1.8853.09
Reata Pharmaceuticals$26.52 million209.05$-290,170,000.00($9.54)-17.15

Catalent has higher revenue and earnings than Reata Pharmaceuticals. Reata Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Catalent has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Comparatively, Reata Pharmaceuticals has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Catalent and Reata Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalent01702.88
Reata Pharmaceuticals00603.00

Catalent currently has a consensus target price of $105.50, indicating a potential upside of 5.71%. Reata Pharmaceuticals has a consensus target price of $257.75, indicating a potential upside of 57.52%. Given Reata Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Reata Pharmaceuticals is more favorable than Catalent.

Institutional and Insider Ownership

91.0% of Catalent shares are owned by institutional investors. Comparatively, 68.3% of Reata Pharmaceuticals shares are owned by institutional investors. 1.0% of Catalent shares are owned by company insiders. Comparatively, 31.7% of Reata Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Catalent and Reata Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalent9.25%14.20%4.83%
Reata Pharmaceuticals-2,237.00%-211.27%-60.78%

Summary

Catalent beats Reata Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Horizon Therapeutics Public (NASDAQ:HZNP) and Reata Pharmaceuticals (NASDAQ:RETA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Earnings & Valuation

This table compares Horizon Therapeutics Public and Reata Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Therapeutics Public$1.30 billion11.89$573.02 million$1.9436.11
Reata Pharmaceuticals$26.52 million209.05$-290,170,000.00($9.54)-17.15

Horizon Therapeutics Public has higher revenue and earnings than Reata Pharmaceuticals. Reata Pharmaceuticals is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Horizon Therapeutics Public has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Reata Pharmaceuticals has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Horizon Therapeutics Public and Reata Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Horizon Therapeutics Public011002.91
Reata Pharmaceuticals00603.00

Horizon Therapeutics Public currently has a consensus target price of $81.1667, indicating a potential upside of 15.87%. Reata Pharmaceuticals has a consensus target price of $257.75, indicating a potential upside of 57.52%. Given Reata Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Reata Pharmaceuticals is more favorable than Horizon Therapeutics Public.

Institutional and Insider Ownership

89.2% of Horizon Therapeutics Public shares are owned by institutional investors. Comparatively, 68.3% of Reata Pharmaceuticals shares are owned by institutional investors. 4.3% of Horizon Therapeutics Public shares are owned by company insiders. Comparatively, 31.7% of Reata Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Horizon Therapeutics Public and Reata Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Horizon Therapeutics Public43.55%25.66%14.19%
Reata Pharmaceuticals-2,237.00%-211.27%-60.78%

Summary

Horizon Therapeutics Public beats Reata Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Elanco Animal Health (NYSE:ELAN) and Reata Pharmaceuticals (NASDAQ:RETA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Elanco Animal Health and Reata Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Elanco Animal Health22702.45
Reata Pharmaceuticals00603.00

Elanco Animal Health currently has a consensus target price of $29.2778, indicating a potential downside of 5.65%. Reata Pharmaceuticals has a consensus target price of $257.75, indicating a potential upside of 57.52%. Given Reata Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Reata Pharmaceuticals is more favorable than Elanco Animal Health.

Volatility & Risk

Elanco Animal Health has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Reata Pharmaceuticals has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500.

Earnings & Valuation

This table compares Elanco Animal Health and Reata Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elanco Animal Health$3.07 billion4.77$67.90 million$1.0629.27
Reata Pharmaceuticals$26.52 million209.05$-290,170,000.00($9.54)-17.15

Elanco Animal Health has higher revenue and earnings than Reata Pharmaceuticals. Reata Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Elanco Animal Health and Reata Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Elanco Animal Health-8.45%3.43%2.04%
Reata Pharmaceuticals-2,237.00%-211.27%-60.78%

Institutional and Insider Ownership

75.9% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 68.3% of Reata Pharmaceuticals shares are owned by institutional investors. 0.1% of Elanco Animal Health shares are owned by company insiders. Comparatively, 31.7% of Reata Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Elanco Animal Health beats Reata Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Reata Pharmaceuticals (NASDAQ:RETA) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Reata Pharmaceuticals and Alnylam Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Reata Pharmaceuticals00603.00
Alnylam Pharmaceuticals161302.60

Reata Pharmaceuticals currently has a consensus price target of $257.75, indicating a potential upside of 57.52%. Alnylam Pharmaceuticals has a consensus price target of $153.4737, indicating a potential upside of 24.76%. Given Reata Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Reata Pharmaceuticals is more favorable than Alnylam Pharmaceuticals.

Volatility and Risk

Reata Pharmaceuticals has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.

Earnings and Valuation

This table compares Reata Pharmaceuticals and Alnylam Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Reata Pharmaceuticals$26.52 million209.05$-290,170,000.00($9.54)-17.15
Alnylam Pharmaceuticals$219.75 million65.04$-886,120,000.00($8.11)-15.17

Reata Pharmaceuticals has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Reata Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Reata Pharmaceuticals and Alnylam Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Reata Pharmaceuticals-2,237.00%-211.27%-60.78%
Alnylam Pharmaceuticals-222.19%-65.96%-31.38%

Institutional and Insider Ownership

68.3% of Reata Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.3% of Alnylam Pharmaceuticals shares are owned by institutional investors. 31.7% of Reata Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Reata Pharmaceuticals (NASDAQ:RETA) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Reata Pharmaceuticals and BioMarin Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Reata Pharmaceuticals00603.00
BioMarin Pharmaceutical0101302.57

Reata Pharmaceuticals currently has a consensus price target of $257.75, indicating a potential upside of 57.52%. BioMarin Pharmaceutical has a consensus price target of $119.6667, indicating a potential upside of 55.33%. Given Reata Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Reata Pharmaceuticals is more favorable than BioMarin Pharmaceutical.

Volatility and Risk

Reata Pharmaceuticals has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Earnings and Valuation

This table compares Reata Pharmaceuticals and BioMarin Pharmaceutical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Reata Pharmaceuticals$26.52 million209.05$-290,170,000.00($9.54)-17.15
BioMarin Pharmaceutical$1.70 billion8.21$-23,850,000.00$0.071,100.57

BioMarin Pharmaceutical has higher revenue and earnings than Reata Pharmaceuticals. Reata Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Reata Pharmaceuticals and BioMarin Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Reata Pharmaceuticals-2,237.00%-211.27%-60.78%
BioMarin Pharmaceutical45.74%4.34%2.84%

Institutional and Insider Ownership

68.3% of Reata Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.4% of BioMarin Pharmaceutical shares are owned by institutional investors. 31.7% of Reata Pharmaceuticals shares are owned by insiders. Comparatively, 2.2% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

BioMarin Pharmaceutical beats Reata Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Reata Pharmaceuticals (NASDAQ:RETA) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Reata Pharmaceuticals and Grifols, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Reata Pharmaceuticals00603.00
Grifols04502.56

Reata Pharmaceuticals currently has a consensus price target of $257.75, indicating a potential upside of 57.52%. Given Reata Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Reata Pharmaceuticals is more favorable than Grifols.

Volatility and Risk

Reata Pharmaceuticals has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.

Earnings and Valuation

This table compares Reata Pharmaceuticals and Grifols' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Reata Pharmaceuticals$26.52 million209.05$-290,170,000.00($9.54)-17.15
Grifols$5.71 billion2.25$700.16 million$1.1715.95

Grifols has higher revenue and earnings than Reata Pharmaceuticals. Reata Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Reata Pharmaceuticals and Grifols' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Reata Pharmaceuticals-2,237.00%-211.27%-60.78%
Grifols10.40%10.83%4.68%

Institutional and Insider Ownership

68.3% of Reata Pharmaceuticals shares are owned by institutional investors. Comparatively, 18.0% of Grifols shares are owned by institutional investors. 31.7% of Reata Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


Reata Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Catalent logo
CTLT
Catalent
1.7$99.80+3.5%$16.44 billion$3.09 billion63.57
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.2$70.05+0.1%$15.46 billion$1.30 billion19.14Analyst Downgrade
Increase in Short Interest
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.9$31.03+5.2%$14.64 billion$3.07 billion-54.44Analyst Report
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$123.02+1.4%$14.29 billion$219.75 million-15.71
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.0$77.04+1.4%$13.99 billion$1.70 billion17.63
Grifols logo
GRFS
Grifols
1.5$18.66+0.9%$12.83 billion$5.71 billion20.73
MyoKardia logo
MYOK
MyoKardia
0.9$224.91+0.0%$11.99 billion$33.56 million-39.88
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.0$225.00+0.8%$11.31 billion$3.34 million-29.22Decrease in Short Interest
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.4$64.06+1.6%$10.62 billion$2.32 billion42.15
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
2.0$134.49+2.5%$10.61 billion$380.83 million-19.16
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
2.0$9.61+1.4%$10.50 billion$16.89 billion4.16
Mylan logo
MYL
Mylan
1.9$15.86+0.0%$8.59 billion$11.50 billion29.92High Trading Volume
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.6$53.84+0.5%$8.56 billion$339.08 million-31.30
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.8$158.48+1.2%$8.37 billion$14.98 million-19.30
Galapagos logo
GLPG
Galapagos
1.3$125.25+0.5%$8.18 billion$1.00 billion-18.98Analyst Report
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$144.31+0.8%$8.04 billion$2.16 billion45.52
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.8$50.27+2.2%$7.03 billion$1.12 billion104.73Unusual Options Activity
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.3$114.69+0.3%$7.00 billion$103.71 million-21.97
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.2$68.20+0.9%$6.98 billion$168.80 million-272.80Earnings Announcement
Analyst Report
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$19.31+1.9%$6.86 billion$8.60 billion-3.54
Perrigo logo
PRGO
Perrigo
2.4$47.75+0.8%$6.52 billion$4.84 billion27.44
United Therapeutics logo
UTHR
United Therapeutics
1.4$137.77+1.3%$6.12 billion$1.45 billion14.14
Zai Lab logo
ZLAB
Zai Lab
1.2$104.96+0.6%$6.10 billion$12.98 million-34.64Decrease in Short Interest
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.2$22.39+1.8%$5.83 billion$182.24 million-19.47
BBIO
BridgeBio Pharma
1.4$46.44+4.8%$5.69 billion$40.56 million-13.62
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.9$98.76+1.1%$5.50 billion$66.51 million18.22Decrease in Short Interest
Allakos logo
ALLK
Allakos
1.0$103.63+2.1%$5.44 billionN/A-37.82Decrease in Short Interest
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.2$88.48+10.9%$5.30 billionN/A-7.21Insider Buying
TPTX
Turning Point Therapeutics
1.7$104.37+1.2%$5.03 billionN/A-28.06Decrease in Short Interest
SDGR
Schrödinger
1.5$67.65+10.4%$4.70 billion$85.54 million0.00Analyst Upgrade
Insider Selling
High Trading Volume
Unusual Options Activity
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.1$62.24+1.4%$4.25 billion$306.98 million-8.87
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$79.67+3.8%$4.22 billion$1.11 billion25.62Heavy News Reporting
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$31.06+3.6%$4.14 billion$204.89 million-38.83
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$77.97+2.3%$4.06 billion$6.87 million-6.61
Insmed logo
INSM
Insmed
0.9$39.18+0.3%$3.99 billion$136.47 million-15.07Analyst Report
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$57.28+2.1%$3.96 billion$36.13 million-85.49
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$30.09+0.8%$3.96 billion$150,000.00-14.47
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.7$125.44+0.5%$3.89 billion$311.33 million-72.93Decrease in Short Interest
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$64.68+0.2%$3.76 billion$806.43 million-9.16
FibroGen logo
FGEN
FibroGen
1.6$40.19+0.8%$3.66 billion$256.58 million-15.40Analyst Downgrade
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.5$47.85+5.1%$3.62 billionN/A-6.45Analyst Report
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.4$61.67+0.7%$3.51 billion$25 million-12.33
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.2$85.09+4.6%$3.29 billion$26.69 million-32.11Decrease in Short Interest
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.5$34.08+1.2%$3.11 billion$34.51 million-32.77Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.8$44.03+1.0%$3.05 billion$117.91 million-8.93Decrease in Short Interest
Analyst Revision
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.7$16.53+1.4%$2.97 billion$114.62 million-6.67
Alkermes logo
ALKS
Alkermes
1.3$18.23+0.1%$2.90 billion$1.17 billion-39.63
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.2$63.92+3.7%$2.78 billion$421.03 million-255.68
KRTX
Karuna Therapeutics
1.6$100.00+3.0%$2.68 billionN/A-49.75
OPKO Health logo
OPK
OPKO Health
1.9$3.99+1.3%$2.67 billion$901.90 million-12.09
This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.